AMNEAL PHARMACEUTICALS, INC. (AMRX) Current Ratio
- Current ratio · latest quarter: Value 2.20×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.20× | Current assets / current liabilities. $1.95B ÷ $883.19M ≈ 2.20× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.95B USD | Assets, Current |
| Current obligations | 883.19M USD | Liabilities, Current |
| Cash and equivalents | 127.64M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 677.95M USD | Inventory, Net |
| Payables | (m) | Accounts Payable, Current |
| Borrowing debt due within one year | 5.96M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.95B | $883.19M | $127.64M | (m) | (m) | $677.95M | (m) | $5.96M | 2.20× |
| 2026-03-31 | $1.80B | $728.05M | $197.66M | (m) | (m) | $641.62M | (m) | $6.20M | 2.47× |
| 2025-12-31 | $1.91B | $881.63M | $282.03M | (m) | (m) | $606.30M | (m) | $6.76M | 2.17× |
| 2025-09-30 | $1.84B | $862.11M | $201.25M | (m) | (m) | $614.50M | $266.36M | $7.20M | 2.13× |
| 2025-06-30 | $1.58B | $1.11B | $71.54M | (m) | (m) | $608.97M | $205.81M | $31.18M | 1.43× |
| 2025-03-31 | $1.51B | $1.08B | $59.19M | (m) | (m) | $601.43M | $192.53M | $31.79M | 1.40× |
| 2024-12-31 | $1.59B | $1.13B | $110.55M | (m) | (m) | $612.45M | (m) | $224.21M | 1.41× |
| 2024-09-30 | $1.51B | $1.10B | $74.01M | (m) | (m) | $596.36M | $235.00M | $224.69M | 1.38× |
| 2024-06-30 | $1.49B | $1.11B | $43.77M | (m) | (m) | $575.62M | $199.58M | $225.16M | 1.33× |
| 2024-03-31 | $1.38B | $834.39M | $46.52M | (m) | (m) | $570.65M | $175.32M | $33.66M | 1.65× |
| 2023-12-31 | $1.38B | $846.60M | $91.54M | (m) | (m) | $581.38M | (m) | $34.13M | 1.63× |
| 2023-09-30 | $1.46B | $760.60M | $86.93M | (m) | (m) | $576.47M | $177.40M | $30.53M | 1.91× |
| 2023-06-30 | $1.42B | $777.35M | $109.28M | (m) | (m) | $550.56M | $139.53M | $30.41M | 1.83× |
| 2023-03-31 | $1.31B | $703.71M | $144.67M | (m) | $545.76M | $529.04M | $136.92M | $29.96M | 1.86× |
| 2022-12-31 | $1.41B | $752.80M | $25.98M | (m) | (m) | $530.74M | (m) | $29.96M | 1.88× |
| 2022-09-30 | $1.42B | $818.00M | $87.33M | (m) | $628.74M | $543.86M | (m) | $29.94M | 1.74× |
| 2022-06-30 | $1.55B | $993.06M | $91.98M | (m) | $688.85M | $533.03M | (m) | $29.92M | 1.56× |
| 2022-03-31 | $1.39B | $602.04M | $210.48M | (m) | $538.31M | $512.24M | (m) | $30.52M | 2.31× |
| 2021-12-31 | $1.52B | $677.24M | $247.79M | (m) | $662.58M | $489.39M | $131.08M | $30.61M | 2.24× |
| 2021-09-30 | $1.57B | $667.34M | $302.65M | (m) | $627.95M | $520.25M | (m) | $30.47M | 2.35× |
| 2021-06-30 | $1.56B | $672.86M | $278.31M | (m) | $652.01M | $523.38M | (m) | $30.46M | 2.32× |
| 2021-03-31 | $1.56B | $636.78M | $452.10M | (m) | $530.60M | $497.01M | (m) | $29.82M | 2.45× |
| 2020-12-31 | $1.55B | $676.90M | $341.38M | (m) | $638.89M | $490.65M | $153.14M | $44.23M | 2.29× |
| 2020-09-30 | $1.54B | $667.89M | $281.28M | (m) | $707.10M | $475.76M | (m) | $29.78M | 2.31× |
| 2020-06-30 | $1.48B | $655.02M | $266.14M | (m) | $582.73M | $443.96M | (m) | $29.76M | 2.26× |
| 2020-03-31 | $1.77B | $965.07M | $405.24M | (m) | $722.68M | $437.96M | (m) | $29.74M | 1.84× |
| 2019-12-31 | $1.21B | $550.41M | $151.20M | (m) | $604.39M | $381.07M | $103.02M | $21.48M | 2.20× |
| 2019-09-30 | $1.21B | $534.91M | $212.74M | (m) | $518.11M | $401.83M | (m) | (m) | 2.25× |
| 2019-06-30 | $1.19B | $546.16M | $54.89M | (m) | $634.67M | $414.63M | (m) | (m) | 2.17× |
| 2019-03-31 | $1.27B | $599.53M | $63.95M | (m) | $640.21M | $448.29M | (m) | (m) | 2.11× |
| 2018-12-31 | $1.29B | $553.85M | $213.39M | (m) | $481.50M | $457.22M | $114.85M | $21.45M | 2.32× |
| 2018-09-30 | $1.43B | $749.27M | $165.19M | (m) | $641.03M | $490.77M | $124.54M | (m) | 1.91× |
| 2018-06-30 | $1.35B | $669.74M | $61.52M | (m) | $626.49M | $512.48M | $169.05M | (m) | 2.01× |
| 2017-12-31 | $771.93M | $296.88M | $74.17M | (m) | $351.37M | $284.04M | $70.01M | $89.17M | 2.60× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |